The chief medical officer of Astellas previews ASCO and talks about new modalities and targets the company has been working on

Tadaaki Taniguchi covers some of the work Astellas is doing with modalities like antibody-drug conjugates, T-cell engagers, and protein degradation, and targets such as Claudin 18.2.